Clinical use of insulin degludec
Open accessThe DOI matches its Crossref record; 29 of the 29 references it cites were found in a registry or an index.
Abstract
The limitations of current basal insulin preparations include concerns related to their pharmacokinetic and pharmacodynamic properties, hypoglycaemia, weight gain, and perception of management complexity, including rigid dosing schedules. Insulin degludec (IDeg) is a novel basal insulin with improved pharmacokinetic and pharmacodynamic properties compared to insulin glargine (IGlar) including a long half-life of ∼25 h and a duration of action >42 h at steady state, providing a flat and stable blood glucose-lowering effect when injected once daily. Evidence from phase 3a clinical trials with a treat-to-target design in patients with type 1 and type 2 diabetes has shown that IDeg has similar efficacy to IGlar, with a 9% and 26% reduction in risk of overall and nocturnal hypoglycaemia, respectively (in the pooled population) during the entire treatment period, and a 16% and 32% reduction during the maintenance period, respectively. Given its pharmacodynamic properties, IDeg offers a broad dosing window, allowing for flexible dose administration, if required. Two different formulations of IDeg are available (100 units/mL [U100] and 200 units/mL), the latter providing the same IDeg dose as the U100 formulation in half the injection volume. The unique pharmacokinetic profile of IDeg facilitates glycaemic control while minimising the risk of nocturnal hypoglycaemia.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Intensive diabetes treatment and cardiovascular disease in patients with type 1 diabetes
(2005) · New England Journal of Medicine · doi:10.1056/nejmoa052187 · Cited by 5,138
Standards of medical care in diabetes—2014
American Diabetes Association (2014) · Diabetes Care · doi:10.2337/dc14-s014 · Cited by 4,572
Inzucchi, S. E., Bergenstal, R. M., Buse, J. B., Diamant, M., Ferrannini, E., Nauck, M., Peters, A. L., Tsapas, A., Wender, R., & Matthews, D. R. (2012) · Diabetologia · doi:10.1007/s00125-012-2534-0 · Cited by 3,919
Biology of Incretins: GLP-1 and GIP
Baggio, L. L., & Drucker, D. J. (2007) · Gastroenterology · doi:10.1053/j.gastro.2007.03.054 · Cited by 3,639 · cited 1×
“[41,42].”
Defining and Reporting Hypoglycemia in Diabetes
American Diabetes Association Workgroup on Hypoglycemia (2005) · Diabetes Care · doi:10.2337/diacare.28.5.1245 · Cited by 1,146
Lepore, M., Pampanelli, S., Fanelli, C., Porcellati, F., Bartocci, L., Di Vincenzo, A., Cordoni, C., Costa, E., Brunetti, P., & Bolli, G. B. (2000) · Diabetes · doi:10.2337/diabetes.49.12.2142 · Cited by 818
Peyrot, M., Barnett, A. H., Meneghini, L. F., & Schumm‐Draeger, P. ‐. (2012) · Diabetic Medicine · doi:10.1111/j.1464-5491.2012.03605.x · Cited by 655 · cited 2×
“This is primarily due to the fear of hypoglycaemia, coupled with the restrictions on patients’ lifestyle that can result from complex or inflexible dosing regimens [8,9].”
BackgroundSelf-citationHeise, T., Nosek, L., Rønn, B. B., Endahl, L., Heinemann, L., Kapitza, C., & Draeger, E. (2004) · Diabetes · doi:10.2337/diabetes.53.6.1614 · Cited by 614
Design of the Novel Protraction Mechanism of Insulin Degludec, an Ultra-long-Acting Basal Insulin
Jonassen, I., Havelund, S., Hoeg-Jensen, T., Steensgaard, D. B., Wahlund, P.-O., & Ribel, U. (2012) · Pharmaceutical Research · doi:10.1007/s11095-012-0739-z · Cited by 448
Heller, S., Buse, J., Fisher, M., Garg, S., Marre, M., Merker, L., Renard, E., Russell-Jones, D., Philotheou, A., Francisco, A. M. O., et al. (2012) · The Lancet · doi:10.1016/s0140-6736(12)60204-9 · Cited by 402
Heise, T., Hermanski, L., Nosek, L., Feldman, A., Rasmussen, S., & Haahr, H. (2012) · Diabetes, Obesity and Metabolism · doi:10.1111/j.1463-1326.2012.01627.x · Cited by 397 · cited 4×
“As a result, the duration of action of IDeg at steady state exceeds 42 h [22,24,26] compared with the mean duration of action of IGlar of 20.”
BackgroundInfluentialRatner, R. E., Gough, S. C. L., Mathieu, C., Del Prato, S., Bode, B., Mersebach, H., Endahl, L., & Zinman, B. (2013) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.12032 · Cited by 346 · cited 10×
“IGlar [53] that has been reported in subjects with T1DM [26] and in those with T2DM [56].”
BackgroundMethodInfluentialInsulin Degludec Versus Insulin Glargine in Insulin-Naive Patients With Type 2 Diabetes
Zinman, B., Philis-Tsimikas, A., Cariou, B., Handelsman, Y., Rodbard, H. W., Johansen, T., Endahl, L., Mathieu, C., & on behalf of the NN1250-3579 (BEGIN Once Long) Trial Investigators (2012) · Diabetes Care · doi:10.2337/dc12-1205 · Cited by 336
Self-citationUltra‐long‐acting insulin degludec has a flat and stable glucose‐lowering effect in type 2 diabetes
Heise, T., Nosek, L., Bøttcher, S. G., Hastrup, H., & Haahr, H. (2012) · Diabetes, Obesity and Metabolism · doi:10.1111/j.1463-1326.2012.01638.x · Cited by 331
Buse, J. B., Vilsbøll, T., Thurman, J., Blevins, T. C., Langbakke, I. H., Bøttcher, S. G., & Rodbard, H. W. (2014) · Diabetes Care · doi:10.2337/dc14-0785 · Cited by 259
Klein, O., Lynge, J., Endahl, L., Damholt, B., Nosek, L., & Heise, T. (2007) · Diabetes, Obesity and Metabolism · doi:10.1111/j.1463-1326.2006.00685.x · Cited by 251 · cited 2×
“[19] Klein O, Lynge J, Endahl L, Damholt B, Nosek L, Heise T.”
BackgroundMeneghini, L., Atkin, S. L., Gough, S. C. L., Raz, I., Blonde, L., Shestakova, M., Bain, S., Johansen, T., Begtrup, K., Birkeland, K. I., et al. (2013) · Diabetes Care · doi:10.2337/dc12-1668 · Cited by 226
Self-citationMathieu, C., Hollander, P., Miranda-Palma, B., Cooper, J., Franek, E., Russell-Jones, D., Larsen, J., Tamer, S. C., Bain, S. C., & on behalf of the NN1250-3770 (BEGIN: Flex T1) Trial Investigators (2013) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2012-3249 · Cited by 219 · cited 7×
“In the T1DM trials included in the meta-analysis [46,47] there”
BackgroundResultInfluentialGough, S. C. L., Bhargava, A., Jain, R., Mersebach, H., Rasmussen, S., & Bergenstal, R. M. (2013) · Diabetes Care · doi:10.2337/dc12-2329 · Cited by 150
Exercise-related hypoglycemia in diabetes mellitus
Younk, L. M., Mikeladze, M., Tate, D., & Davis, S. N. (2011) · Expert Review of Endocrinology & Metabolism · doi:10.1586/eem.10.78 · Cited by 114
Onishi, Y., Iwamoto, Y., Yoo, S. J., Clauson, P., Tamer, S. C., & Park, S. (2013) · Journal of Diabetes Investigation · doi:10.1111/jdi.12102 · Cited by 102
Korsatko, S., Deller, S., Koehler, G., Mader, J. K., Neubauer, K., Adrian, C. L., Thomsen, H., Haahr, H., & Pieber, T. R. (2013) · Clinical Drug Investigation · doi:10.1007/s40261-013-0096-7 · Cited by 89 · cited 3×
“As discussed, there are two different formulations of IDeg: 100 units/mL (U100) and 200 units/mL (U200), which have been shown to be bioequivalent [33].”
BackgroundInfluentialAlbright, E. S., Desmond, R., & Bell, D. S. H. (2004) · Diabetes Care · doi:10.2337/diacare.27.2.632 · Cited by 75 · cited 2×
“IGlar is recommended for once-daily dosing and IDet for once- or twice-daily dosing; however, in clinical practice, more frequent than once-daily dosing of either of these basal insulin preparations may offer improved glycaemic control of blood glucose in some cases [13–17].”
BackgroundInsulin Degludec: Pharmacokinetics in Patients with Renal Impairment
Kiss, I., Arold, G., Roepstorff, C., Bøttcher, S. G., Klim, S., & Haahr, H. (2014) · Clinical Pharmacokinetics · doi:10.1007/s40262-013-0113-2 · Cited by 75 · cited 3×
“the elderly and those with hepatic or renal impairment (including those with end-stage renal disease) [30–32].”
BackgroundAshwell, S. G., Gebbie, J., & Home, P. D. (2006) · Diabetic Medicine · doi:10.1111/j.1464-5491.2005.01726.x · Cited by 53 · cited 2×
“IGlar is recommended for once-daily dosing and IDet for once- or twice-daily dosing; however, in clinical practice, more frequent than once-daily dosing of either of these basal insulin preparations may offer improved glycaemic control of blood glucose in some cases [13–17].”
BackgroundGlucose-Lowering Effect of Insulin Degludec is Independent of Subcutaneous Injection Region
Nosek, L., Coester, H.-V., Roepstorff, C., Thomsen, H. F., Kristensen, N. R., Haahr, H., & Heise, T. (2014) · Clinical Drug Investigation · doi:10.1007/s40261-014-0218-x · Cited by 42
Insulin Degludec: Pharmacokinetic Properties in Subjects with Hepatic Impairment
Kupčová, V., Arold, G., Roepstorff, C., Højbjerre, M., Klim, S., & Haahr, H. (2014) · Clinical Drug Investigation · doi:10.1007/s40261-013-0154-1 · Cited by 40 · cited 3×
“the elderly and those with hepatic or renal impairment (including those with end-stage renal disease) [30–32].”
BackgroundKorsatko, S., Deller, S., Mader, J. K., Glettler, K., Koehler, G., Treiber, G., Urschitz, M., Wolf, M., Hastrup, H., Søndergaard, F., et al. (2014) · Drugs & Aging · doi:10.1007/s40266-013-0138-0 · Cited by 37 · cited 3×
“the elderly and those with hepatic or renal impairment (including those with end-stage renal disease) [30–32].”
BackgroundKoehler, G., Heller, S., Korsatko, S., Roepstorff, C., Rasmussen, S., Haahr, H., & Pieber, T. R. (2014) · Diabetologia · doi:10.1007/s00125-013-3056-0 · Cited by 29 · cited 2×
“[54] Koehler G, Heller S, Korsatko S, Roepstorff C, Rasmussen S, Haahr H, et al.”
BackgroundResult
Cited by
Glycemic Variability: How Do We Measure It and Why Is It Important?
Suh, S., & Kim, J. H. (2015) · Diabetes & Metabolism Journal · doi:10.4093/dmj.2015.39.4.273 · Cited by 439
Insulin-associated weight gain in obese type 2 diabetes mellitus patients: What can be done?
Brown, A., Guess, N., Dornhorst, A., Taheri, S., & Frost, G. (2017) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.13009 · Cited by 113
“action up to 24 hours, on limiting IAWG, although the risk of hypoglycaemia was reduced.(100,101)”
BackgroundZhang, X.-W., Zhang, X.-L., Xu, B., & Kang, L.-N. (2018) · Acta Diabetologica · doi:10.1007/s00592-018-1107-1 · Cited by 44
Understanding concentrated insulins: a systematic review of randomized controlled trials
Ovalle, F., Segal, A. R., Anderson, J. E., Cohen, M. R., Morwick, T. M., & Jackson, J. A. (2018) · Current Medical Research and Opinion · doi:10.1080/03007995.2017.1409426 · Cited by 16
Metadata
- Authors
- Vora, J., Cariou, B., Evans, M., Gross, J. L., Harris, S., Landstedt-Hallin, L., Mithal, A., Rodriguez, M. R., & Meneghini, L.
- Venue
- Diabetes Research and Clinical Practice
- Publisher
- Elsevier BV
- Published
- 2015-07
- Volume
- 109
- Issue
- 1
- Pages
- 19-31
- ISSN
- 0168-8227 (ISSN-L)
- OpenAlex
- W2102619124
- Cited by
- 73
- References
- 29
- FWCI
- 9.11
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.